[go: up one dir, main page]

MEP32308A - Pharmaceutical composition containing histone deacetylase inhibitor - Google Patents

Pharmaceutical composition containing histone deacetylase inhibitor

Info

Publication number
MEP32308A
MEP32308A MEP-323/08A MEP32308A MEP32308A ME P32308 A MEP32308 A ME P32308A ME P32308 A MEP32308 A ME P32308A ME P32308 A MEP32308 A ME P32308A
Authority
ME
Montenegro
Prior art keywords
histone deacetylase
deacetylase inhibitor
pharmaceutical composition
composition containing
containing histone
Prior art date
Application number
MEP-323/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MEP32308A publication Critical patent/MEP32308A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-323/08A 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor MEP32308A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
YUP-2005/0884A RS20050884A (sr) 2003-05-26 2004-05-26 Farmaceutski preparat koji sadrži inhibitor histonske deacetilaze

Publications (1)

Publication Number Publication Date
MEP32308A true MEP32308A (en) 2010-10-10

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-323/08A MEP32308A (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Country Status (27)

Country Link
US (1) US20070098816A1 (xx)
EP (1) EP1626719A1 (xx)
JP (1) JP2006526031A (xx)
KR (1) KR100938712B1 (xx)
CN (2) CN101322707A (xx)
AR (1) AR045318A1 (xx)
AU (1) AU2004241873C1 (xx)
BR (1) BRPI0410959A (xx)
CA (4) CA2634765A1 (xx)
CL (1) CL2004001278A1 (xx)
CO (1) CO5660262A2 (xx)
CR (1) CR8163A (xx)
CU (1) CU23490B7 (xx)
EC (1) ECSP056253A (xx)
IL (1) IL171941A0 (xx)
ME (1) MEP32308A (xx)
MX (1) MXPA05012345A (xx)
NO (1) NO20055417L (xx)
NZ (1) NZ543591A (xx)
PE (1) PE20050206A1 (xx)
RS (1) RS20050884A (xx)
RU (1) RU2322971C2 (xx)
TW (1) TW200505424A (xx)
UA (1) UA81499C2 (xx)
UY (1) UY28330A1 (xx)
WO (1) WO2004103369A1 (xx)
ZA (1) ZA200509515B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
MXPA06003222A (es) * 2003-09-25 2006-05-22 Astellas Pharma Inc Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006099396A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
CA2601706C (en) 2005-03-22 2016-09-20 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
EP1991247B1 (en) 2006-02-14 2015-10-14 President and Fellows of Harvard College Bifunctional histone deacetylase inhibitors
JP5409015B2 (ja) * 2006-02-14 2014-02-05 プレジデント アンド フェロウズ オブ ハーバード カレッジ ヒストンデアセチラーゼ阻害剤
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US9408816B2 (en) 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
AU2008338631A1 (en) * 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
EP2321264B1 (en) 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
HRP20120183T8 (xx) * 2008-08-29 2012-11-30 Bayer Pharma Aktiengesellschaft N-(2-aminofenil)-4-[n-(piridin-3-il)-metoksikarbonilaminometil]-benzamid (ms-275)polimorf b
AU2009327357C1 (en) 2008-12-19 2017-02-02 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of ATR kinase
US20120034302A1 (en) * 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
JP2012525371A (ja) * 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド 癌を治療するためのペンタミジンの組み合わせ
EP2440519A1 (en) * 2009-06-08 2012-04-18 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
SG178873A1 (en) * 2009-08-25 2012-04-27 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
SG11201401095YA (en) * 2011-09-30 2014-04-28 Vertex Pharma Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
RS59337B1 (sr) 2011-09-30 2019-10-31 Vertex Pharma Postupak za izradu jedinjenja, korisnih kao inhibitori atr kinaze
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
ES2654670T3 (es) 2012-04-05 2018-02-14 Vertex Pharmaceuticals Incorporated Compuestos útiles como inhibidores de la cinasa ATR y terapias de combinación de los mismos
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
WO2014164708A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
JP6723663B2 (ja) 2014-09-17 2020-07-15 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
JP3354090B2 (ja) 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
WO2000018393A1 (en) * 1998-09-25 2000-04-06 Warner-Lambert Company Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
AU4144400A (en) * 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
KR20020060226A (ko) * 1999-11-10 2002-07-16 로즈 암스트롱, 크리스틴 에이. 트러트웨인 배합 화학요법
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
RU2005140570A (ru) 2006-06-10
IL171941A0 (en) 2006-04-10
BRPI0410959A (pt) 2006-07-04
UA81499C2 (en) 2008-01-10
CO5660262A2 (es) 2006-07-31
TW200505424A (en) 2005-02-16
CA2634765A1 (en) 2004-12-02
CA2634766A1 (en) 2004-12-02
CN1794991A (zh) 2006-06-28
AU2004241873B2 (en) 2008-05-08
US20070098816A1 (en) 2007-05-03
WO2004103369A1 (en) 2004-12-02
ZA200509515B (en) 2006-07-26
UY28330A1 (es) 2004-12-31
EP1626719A1 (en) 2006-02-22
CA2634709A1 (en) 2004-12-02
RU2322971C2 (ru) 2008-04-27
PE20050206A1 (es) 2005-03-26
NO20055417L (no) 2005-12-19
CU23490B7 (es) 2010-02-23
JP2006526031A (ja) 2006-11-16
AU2004241873A1 (en) 2004-12-02
NO20055417D0 (no) 2005-11-16
ECSP056253A (es) 2006-10-25
CL2004001278A1 (es) 2005-05-06
AU2004241873B8 (en) 2008-05-29
CN101322707A (zh) 2008-12-17
RS20050884A (sr) 2008-04-04
CR8163A (es) 2006-07-14
CA2527191A1 (en) 2004-12-02
KR20060009371A (ko) 2006-01-31
MXPA05012345A (es) 2006-02-08
AR045318A1 (es) 2005-10-26
AU2004241873C1 (en) 2009-01-22
KR100938712B1 (ko) 2010-01-25
NZ543591A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
MEP32308A (en) Pharmaceutical composition containing histone deacetylase inhibitor
NO20055216L (no) Nye hydroksamater som terapeutiske midler
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
NO20044314L (no) Sulfonyldenvater som nye inhibitorer av histon-deacetylase
NO20044135L (no) Piperazinyl-, piperidinyl- og morfolinylderivater som nye inhibitorer av histon-deacetylase
ZA202004023B (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
EA200401200A1 (ru) Карбониламинопроизводные как новые ингибиторы гистондеацетилазы
NO20044444L (no) Benzamidderivater nyttige som histondeacetylase inhibitorer
CY1109331T1 (el) Παραγωγα αμινοφαινυλιου ως νεοι αναστολεις της αποακετυλασης ιστονης
NO20044194L (no) Nye inhibitorer av histon-deacetylase
ME00566A (en) Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
AR042851A1 (es) Acidos hidroxamicos inhibidores de histona desacetilasa
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
IL185882A0 (en) Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
EA200700143A1 (ru) Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы
HUE068516T2 (hu) 1,3,4-Oxadiazol-származék vegyületek mint hiszton-deacetiláz-6 inhibitorok és ilyen vegyületeket tartalmazó gyógyászati kompozíció
MX2013004117A (es) Formulacion farmaceutica para inhibidores de histona desacetilasa.
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
PT4110780T (pt) Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
SV2006002109A (es) Una composicion farmaceutica antimicobacteriana
EA201992296A1 (ru) Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета
PE20212078A1 (es) Inhibidor de mpges 1 para el tratamiento de dolor de osteoartritis
TH81162A (th) สารผสมทางเภสัชกรรมที่มีตัวยับยั้งฮิสโตนดีอะซีทิลเลส
TH81162B (th) สารผสมทางเภสัชกรรมที่มีตัวยับยั้งฮิสโตนดีอะซีทิลเลส
HK1119669A (en) Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them